Theravance Biopharma, Inc. (TBPH) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $652.00K; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $652.00K | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $652.00K |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | (m) | |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 652.00K USD | Accounts Payable, Current |
| Total deferred revenue | (m) | Contract with Customer, Liability, Current · Deferred Revenue, Current · Contract with Customer, Liability, Noncurrent · Deferred Revenue, Noncurrent |
| Deferred revenue due within one year | (m) | Contract with Customer, Liability, Current · Deferred Revenue, Current |
| Deferred revenue due after one year | (m) | Contract with Customer, Liability, Noncurrent · Deferred Revenue, Noncurrent · Contract with Customer, Liability, Current · Deferred Revenue, Current |
| Reported other obligations due within one year | (m) | Other Liabilities, Current |
| Reported other noncurrent obligations | 244.00K USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) | Contract with Customer, Liability, Current · Deferred Revenue, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $38.57M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $652.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $244.00K | (m) |
| 2026-03-31 | (m) | $1.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $244.00K | (m) |
| 2025-12-31 | (m) | $2.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $313.00K | (m) |
| 2025-09-30 | (m) | $2.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $313.00K | (m) |
| 2025-06-30 | (m) | $1.68M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.55M | (m) |
| 2025-03-31 | (m) | $2.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.29M | (m) |
| 2024-12-31 | (m) | $2.24M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.89M | (m) |
| 2024-09-30 | (m) | $1.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.98M | (m) |
| 2024-06-30 | (m) | $1.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.88M | (m) |
| 2024-03-31 | (m) | $1.69M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $5.45M | (m) |
| 2023-12-31 | (m) | $1.52M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $5.92M | (m) |
| 2023-09-30 | (m) | $2.37M | $199.00K | (m) | $7.68M | (m) | (m) | $24.00K | $175.00K | $7.68M | $0.00 |
| 2023-06-30 | (m) | $1.57M | $205.00K | (m) | $7.68M | (m) | (m) | $24.00K | $181.00K | $7.68M | $0.00 |
| 2023-03-31 | (m) | $2.66M | $211.00K | (m) | $7.68M | (m) | (m) | $24.00K | $187.00K | $7.68M | $0.00 |
| 2022-12-31 | (m) | $1.55M | $216.00K | (m) | $1.66M | (m) | (m) | $24.00K | $192.00K | $1.66M | $0.00 |
| 2022-09-30 | (m) | $5.34M | $223.00K | (m) | $1.66M | (m) | (m) | $24.00K | $199.00K | $1.66M | $0.00 |
| 2022-06-30 | (m) | $3.07M | $228.00K | (m) | $2.40M | (m) | (m) | $24.00K | $204.00K | $2.40M | $0.00 |
| 2022-03-31 | (m) | $1.51M | $399.00K | (m) | $2.43M | (m) | (m) | $98.00K | $301.00K | $2.43M | $0.00 |
| 2021-12-31 | (m) | $3.10M | $408.00K | (m) | $2.42M | (m) | (m) | $98.00K | $310.00K | $2.42M | $0.00 |
| 2021-09-30 | (m) | $8.90M | $3.22M | (m) | $2.61M | (m) | (m) | $2.90M | $320.00K | $2.61M | $0.00 |
| 2021-06-30 | (m) | $10.70M | $6.02M | (m) | $1.83M | (m) | (m) | $5.69M | $329.00K | $1.83M | $0.00 |
| 2021-03-31 | (m) | $6.83M | $8.00M | (m) | $2.06M | (m) | (m) | $7.66M | $339.00K | $2.06M | $0.00 |
| 2020-12-31 | (m) | $6.78M | $11.87M | (m) | $1.83M | (m) | (m) | $11.52M | $348.00K | $1.83M | $0.00 |
| 2020-09-30 | (m) | $6.44M | $18.95M | (m) | $9.70M | (m) | (m) | $18.20M | $750.00K | $9.70M | $0.00 |
| 2020-06-30 | (m) | $10.06M | $26.22M | (m) | $9.61M | (m) | (m) | $25.06M | $1.15M | $9.61M | $0.00 |
| 2020-03-31 | (m) | $6.64M | $31.70M | (m) | $9.58M | (m) | (m) | $23.19M | $8.51M | $9.58M | $0.00 |
| 2019-12-31 | (m) | $4.76M | $38.34M | (m) | $21.29M | (m) | (m) | $31.57M | $6.76M | $21.29M | $0.00 |
| 2019-09-30 | (m) | $8.71M | $47.92M | (m) | $8.90M | (m) | (m) | $33.75M | $14.17M | $8.90M | $0.00 |
| 2019-06-30 | (m) | $3.50M | $56.76M | (m) | $14.46M | (m) | (m) | $43.31M | $13.44M | $14.46M | $0.00 |
| 2019-03-31 | (m) | $5.60M | $64.25M | (m) | $14.26M | (m) | (m) | $42.52M | $21.73M | $14.26M | $0.00 |
| 2018-12-31 | (m) | $9.03M | $69.58M | (m) | $24.76M | (m) | (m) | $43.40M | $26.18M | $24.76M | $0.00 |
| 2018-09-30 | (m) | $3.75M | $79.71M | (m) | $28.32M | (m) | (m) | $57.24M | $22.47M | $28.32M | $0.00 |
| 2018-06-30 | (m) | $3.64M | $88.70M | (m) | $28.32M | (m) | (m) | $54.48M | $34.22M | $28.32M | $0.00 |
| 2018-03-31 | (m) | $5.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $36.09M | (m) |
| 2017-12-31 | (m) | $5.92M | (m) | (m) | (m) | (m) | (m) | $125.00K | (m) | $36.26M | (m) |
| 2017-09-30 | (m) | $5.62M | (m) | (m) | (m) | (m) | (m) | $134.00K | (m) | $26.49M | (m) |
| 2017-06-30 | (m) | $6.41M | (m) | (m) | (m) | (m) | (m) | $142.00K | (m) | $19.00M | (m) |
| 2017-03-31 | (m) | $3.63M | (m) | (m) | (m) | (m) | (m) | $142.00K | (m) | $18.49M | (m) |
| 2016-12-31 | (m) | $1.73M | (m) | (m) | (m) | (m) | (m) | $152.00K | (m) | $13.11M | (m) |
| 2016-09-30 | (m) | $5.35M | (m) | (m) | (m) | (m) | (m) | $218.00K | (m) | $8.85M | (m) |
| 2016-06-30 | (m) | $7.41M | (m) | (m) | (m) | (m) | (m) | $662.00K | (m) | $3.88M | (m) |
| 2016-03-31 | (m) | $9.09M | (m) | (m) | (m) | (m) | (m) | $1.12M | (m) | $3.74M | (m) |
| 2015-12-31 | (m) | $18.80M | (m) | (m) | (m) | (m) | (m) | $144.00K | (m) | $2.98M | (m) |
| 2015-09-30 | (m) | $5.96M | (m) | $4.32M | (m) | (m) | (m) | $271.00K | (m) | $2.79M | (m) |
| 2015-06-30 | (m) | $6.33M | (m) | $3.33M | (m) | (m) | (m) | $342.00K | (m) | $2.43M | (m) |
| 2015-03-31 | (m) | $4.02M | (m) | $7.46M | (m) | (m) | (m) | $310.00K | (m) | $1.89M | (m) |
| 2014-12-31 | (m) | $9.92M | (m) | $5.22M | (m) | (m) | (m) | $89.00K | (m) | $1.58M | (m) |
| 2014-09-30 | (m) | $5.28M | (m) | $4.34M | (m) | (m) | (m) | $667.00K | (m) | $986.00K | (m) |
| 2014-06-30 | (m) | $9.50M | $6.45M | $4.54M | (m) | (m) | (m) | $5.72M | $729.00K | (m) | $0.00 |
| 2014-06-02 | (m) | (m) | (m) | $4.94M | (m) | (m) | (m) | $6.69M | (m) | (m) | (m) |
| 2014-03-31 | (m) | $4.98M | $8.38M | $2.52M | (m) | (m) | (m) | $7.73M | $648.00K | (m) | $0.00 |
| 2013-12-31 | (m) | $6.94M | $8.79M | $2.12M | (m) | (m) | (m) | $8.21M | $585.00K | (m) | $0.00 |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |